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Abstract
Background: A limitation of both culture-based and molecular methods of screening for staphylococcal infection is
that current tests determine only the presence or absence of colonization with no information on the colonizing
strain type. A technique that couples polymerase chain reaction to mass spectrometry (PCR/ESI-MS) has recently
been developed and an assay validated to identify and genotype S. aureus and coagulase-negative staphylococci
(CoNS).
Methods: This study was conducted to determine the rates, risk factors, and molecular genotypes of colonizing
Staphylococcus aureus in adult patients presenting to an inner-city academic emergency department. Participants
completed a structured questionnaire to assess hospital and community risks for infection with methicillin-resistant
S. aureus (MRSA). Nasal swabs were analyzed by PCR/ESI-MS to identify and genotype S. aureus and CoNS.
Results: Of 200 patients evaluated, 59 were colonized with S. aureus; 27 of these were methicillin-resistant strains.
Twenty-four of the 59 S. aureus carriers were co-colonized with a CoNS and 140 of the 200 patients were colonized
exclusively with CoNS. The molecular genotypes of the 59 S. aureus strains were diverse; 21 unique molecular
genotypes belonging to seven major clonal complexes were identified. Eighty-five of 200 patients carried strains
with high-level mupirocin resistance. Of these eighty-five participants, 4 were colonized exclusively with S. aureus,
16 were co-colonized with S. aureus and CoNS, and 65 were colonized exclusively with CoNS.
Conclusion: The prevalence of S. aureus and methicillin-resistant S. aureus colonization in a random sample of
patients seeking care in Emergency Department was 29.5% and 13.5%, respectively. A substantial fraction of the S.
aureus-colonized patients were co-colonized with CoNS and high-level mupirocin-resistant CoNS. Determining the
molecular genotype of S. aureus during intake screening may prove valuable in the future if certain molecular
genotypes become associated with increased infection risk.
Background
Staphylococcus aureus is a major cause of healthcare-
associated infections [1]. Although several epidemio-
logical studies have provided information on the prevalence
of methicillin-resistant Staphylococcus aureus (MRSA)
colonization in different hospital settings [2-4] and in
emergency department personnel [5,6], limited data
exist on MRSA colonization rates for patients seen in
emergency departments. The cost benefit of screening
for MRSA colonization is not overwhelming and the
subject is controversial [7]. A limitation of both culture-
based and molecular methods of MRSA screening is that
current tests determine only the presence or absence of
colonization with no information on the colonizing strain
type [8]. As only small subsets of MRSA clones have been
responsible for the major epidemics in the United States
[9] screening might have greater value if future studies
demonstrate that certain clones are more likely to cause
serious infections than others.
We have developed a rapid molecular surveillance
assay based on PCR coupled to electrospray ionization
mass spectrometry (PCR/ESI-MS) [10-12] that identifies
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and provides detailed information about S. aureus
strains. A previous version of this assay has been shown
to accurately genotype S. aureus strains and to identify
the clonal complex of a series of isolates from the Cen-
ters for Disease Control (CDC). Excellent agreement
with multilocus sequence typing (MLST) and pulsed-
field gel electrophoresis (PFGE) results [13] was reached
using in the PCR/ESI-MS assay a set of eight primer
pairs that target the same genes as those for MLST. This
set of primer pairs was designed to optimize the infor-
mation content of the amplicons and distinguished 99%
of 710 distinct S. aureus sequence types [13]. Using a
second set of eight primer pairs, PCR/ESI-MS has also
been used to characterize virulence factors, toxin-
encoding genes and antibiotic resistance determinants
on isolated colonies [14] and to detect MRSA in nasal
swabs with sensitivity and specificity similar to culture
methods [15]. In this work, elements from the previous
studies were consolidated into a single PCR/ESI-MS re-
search application to directly screen nasal swabs from




This prospective surveillance study of a convenience
sample of adult patients was conducted in the Johns
Hopkins Emergency Department, Maryland, from August
2008 to February 2009. The Johns Hopkins Hospital
Emergency Department sees approximately 5,000 pa-
tients a month. An urgent care center (UCC, 12 beds)
and a dedicated ‘Short-Stay’ emergency acute care unit
(EACU, 17 beds) are also part of emergency department
services and these patients were included in the study.
Subject selection
All patients visiting the adult emergency department for
evaluation and potential treatment were eligible for the
study with the exception of prisoners and patients unable
to understand the study requirements. The enrollment of
patients was a sample of convenience during hours when
the study coordinator was available and included patients
seen Monday-Friday during the hours of 9:30 AM-
5:00 PM. We excluded patients with previously known risk
factors for MRSA colonization [16-18] such as patients with
fever greater than 100.4°F, abscesses, cellulitis, infected
wounds, and known previous MRSA infections, and history
of injection drug use. Three hundred patients were
approached for participation; two-thirds of which met all
study criteria and ultimately consented to participate in the
study. All participants provided verbal informed consent.
This study was approved by the Johns Hopkins Institutional
Review Board.
Collection of clinical specimens
Anterior nasal specimens were obtained using BBL Cul-
ture Swab Plus double applicators (Becton Dickinson,
Sparks, MD) from 200 patients. Swabs were inserted
into both left and right nostril of each study subject.
One study coordinator collected all specimens.
Analysis of clinical specimens
Swabs were inoculated into mannitol salts broth and
allowed to sit for 5 minutes at room temperature. The
swabs were then expressed into broth and incubated at
37°C for 4 hours. After this incubation, 300 μl of the sample
was added to a tube containing zirconia beads and 200 μl
of lysis buffer, and the sample was subjected to bead beating
for 10 minutes (BioSpec Mini Bead Beater, Bartlesville,
OK). Supernatants were transferred to a King Fisher 96-
well processor and nucleic acids were isolated using the
Ambion Total Nucleic acid (TNA) kit (Ambion, Austin,
TX). Nucleic acids were analyzed in eight PCR reactions
containing the duplex PCR primer pairs (Table 1) on PCR/
ESI-MS platform (available for research applications only;
Ibis Biosciences, Abbott, Carlsbad, CA). To determine the
methicillin-resistance status of specimens from patients co-
colonized with S. aureus and CoNS, samples were streaked
on a ChromAgar (Becton Dickinson Biosciences, San Jose,
CA) plate and incubated for 48 hours at 37°C.
Staphylococcus aureus genotyping and characterization
assay
In this study we combined elements from the previous
genotyping [13] and characterization [14] assays into a sin-
gle format and added primer pairs to interrogate the gene
for toxic shock syndrome toxin 1 (TSST-1) [19], the PVL
genes (distinguishing the “R” and “H” variants) [20] and the
region of the ileS gene that encodes low level mupirocin re-
sistance [21,22]. Thus, the current assay, (Figure 1), used
eight amplification/mass spectrometry measurements to
simultaneously detect the gene fragments useful for
Staphylococcus genotyping and to unambiguously identify S.
aureus and S. lugdunensis by distinguishing these species
from each other as well as other coagulase-negative
staphylococcal species. In addition, for S. aureus detections,
the presence or absence of PVL (with a distinction between
the “R” and “H” variants), the mecA gene, the gene encod-
ing TSST-1, and the genes encoding high level (mupA) and
low level (ileS) mupirocin resistance were determined along
with the clonal complex. The turn-around time of the assay
in this study, including the time for analysis was under 8
hours for the first 12 samples. Up to 100 samples can be
analyzed in a 24 hours period.
Risk factor evaluation
A structured nine-item questionnaire was designed based
on review of the relevant literature, to identify patient
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demographic and other characteristics for hospital and/or
community MRSA acquisition. Information collected in-
cluded patient demographics (age, sex, race), a reason for
visit to ED, whether they had a history of prescribed anti-
biotic, or history of admission to the hospital. Patient med-
ical records were reviewed to provide clarification.
Statistics
Prevalence estimates were calculated to estimate the pro-
portion of emergency department patients with MRSA
colonization. Identification of clinical features associated
with MRSA colonization was initially assessed using
bivariate analysis. Variables collected on the patient data
sheet relating to MRSA colonization were entered into a bi-
variate logistic regression model to generate odds ratios
and corresponding 95% confidence intervals of these fac-
tors, controlling for potential confounders.
Results
Genotype and characterization analyses
A total of 200 individuals were recruited and met eligi-
bility criteria for this study. Demographic information
for the 200 study participants is presented in Table 2.
The results for PCR/ESI-MS analysis of nasal swabs
Table 1 Primer pairs used in the PCR/ESI-MS MRSA typing and characterization assay
Rowa Primer pair
code
Target(s) Accession number and
coordinates
Forward and reverse primer sequences Reference
A BCT879 mecA Y14051 5′-TCAGGTACTGCTATCCACCCTCAA-3′ [14]
4507..4581 5′-TGGATAGACGTCATATGAAGGTGTGCT-3′
BCT2157 pta NC_003923 5′-TCTTGTTTATGCTGGTAAAGCAGATGG-3′ [13]
629121..629229 5′-TGGTACACCTGGTTTCGTTTTGATGATTTGTA-3′
B BCT2249 tufB NC_002758.2 5′-TGAACGTGGTCAAATCAAAGTTGGTGAAGA-3′ [14]
615038..616222 5′-TGTCACCAGCTTCAGCGTAGTCTAATAA-3′
BCT2163 yqi NC_003923 5′-TGAATTGCTGCTATGAAAGGTGGCTT-3′ [13]
379057..379199 5′-TCGCCAGCTAGCACGATGTCATTTTC-3′
C BCT3016 mupA X75439 5′-TAGATAATTGGGCTCTTTCTCGCTTAAAC-3′ [14]
2482..2573 5′-TAATCTGGCTGCGGAAGTGAAAT-3′
BCT2161 tpi NC_003923 5′-TCCCACGAAACAGATGAAGAAATTAACAAAAAAG-3′ [13]
830671..830799 5′-TGGTACAACATCGTTAGCTTTACCACTTTCACG-3′
D BCT3106 TSST1 NC_002758.2 5′-TCGTCATCAGCTAACTCAAATACATGGA-3′ This work
519..620 5′-TCACTTTGATATGTGGATCCGTCATTCA-3′
BCT3025 arcC NC_003923 5′-TGAATAGTGATAGAACTGTAGGCACAATCGT-3′ [13]
2724791..2724920 5′-TGCGCTAATTCTTCAACTTCTTCTTTCGT-3′
E BCT2095 PVL genes, lukE-lukD NC_003923 5′-TGAGCTGCATCAACTGTATTGGATAG-3′ [14]
1529595..1531285 5′-TGGAAAACTCATGAAATTAAAGTGAAAGGA-3′
BCT2149 aroE NC_003923 5′-TGGGGCTTTAAATATTCCAATTGAAGATTTTCA-3′ [13]
1674546..1674697 5′-TACCTGCATTAATCGCTTGTTCATCAA-3′
F BCT2256 nuc NC_002758.2 5′-TACAAAGGTCAACCAATGACATTCAGACTA-3′ [14]
894288..894974 5′-TAAATGCACTTGCTTCAGGGCCATAT-3′
BCT2166 yqi NC_003923 5′-TAGCTGGCGGTATGGAGAATATGTCT-3′ [13]
379190..379311 5′-TCCATCTGTTAAACCATCATATACCATGCTATC-3′
G BCT4022 PVL / lukD NC_003923 5′-TGGTCAACAAAGCTATATCAGTGAAGTAGAAC-3′ This work
1529595..1531285 5′-TGGATCATGTCCAGACATTTCACCTAATG-3′
BCT2156 gmk NC_003923 5′-TCACCTCCAAGTTTAGATCACTTGAGAGA-3′ [13]
1191206..1191337 5′-TGGGACGTAATCGTATAAATTCATCATTTC-3′
H BCT4024 ileS NC_002758.2 5′-TCAGTTGCTACAAGAGGAGTATCACCT-3′ This work
1247700..1250453 5′-TACTCATCTTCTTACCTTCACCGTCCATA-3′
BCT2150 aroE NC_003923 5′-TGATGGCAAGTGGATAGGGTATAATACAG-3′ [13]
1674392..1674523′ 5′-TAAGCAATACCTTTACTTGCACCACCTG-3′
aRow indicates the row of a 96-well assay plate. Two primer pairs are present in each well of the assay plate.
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from the participants are illustrated in Figure 2. The pri-
mer set used to analyze the nasal swabs contains a pri-
mer pair targeted to the highly conserved tufB gene that
amplifies all species within the Staphylococcus genus but
not other bacterial genera. Differences in masses of the
amplicons in the mass spectra distinguish S. aureus and
S. lugdunensis from all other species of staphylococci
and identify S. aureus and CoNS. When both are present
in a patient’s sample, spectral peaks from each species
are observed in the same spectrum. Similarly, a primer
pair targeted to the gmk gene, which is part of the geno-
typing component of the assay, also amplifies and distin-
guishes S. aureus and CoNS.
Of 200 patients presenting to the emergency department,
59 (29.5%) were colonized with S. aureus; 24 of these pa-
tients were also co-colonized with CoNS (Figure 2). One
hundred forty of the 200 (70%) were colonized exclusively
with CoNS. Only one patient showed no evidence of
staphylococcal colonization.
The distribution of the mecA gene (the methicillin resist-
ance gene) and the mupA gene (responsible for high level
mupirocin resistance) among the detected Staphylococcus
species is also reported in Figure 2. Of 35 patients colonized
only with S. aureus, 18 were methicillin-sensitive S. aureus
(MSSA) and 17 were MRSA. Of these 18 MSSA patients,
11.1% (2/18) were colonized with strains that carried the
gene for high-level mupirocin resistance. Of 17 MRSA iso-
lates, 11.8% (2/17) had the mupirocin resistance gene. Of
140 CoNS positive patients, 8.6% (12/140) were colonized
with strains that had only the mupirocin resistance gene,
31.4% (44/140) had only methicillin resistance genes and
37.9% (53/140) had genes encoding both methicillin and
mupirocin resistance.
Among the 24 patients who were co-colonized, 66.7%
(16/24) had colonies with both methicillin and high-level
mupirocin resistance, while 33.3% (8/24) had methicillin
resistance only. In those co-colonizations, the location of
the antibiotic resistance genes could not be determined
directly by PCR/ESI-MS (as the same amplicon is pro-
duced irrespective of the bacterial strain); instead, the
species carrying the gene was determined by plating
samples on ChromAgar in order to demonstrate more
than one colony type. Since in ten instances methicillin
resistance could thus be attributed to S. aureus, 45.8%
(27/59) of patients colonized with S. aureus were indeed
colonized with MRSA. Also, 85 patients altogether were
colonized with strains that carried the gene encoding
high-level mupirocin resistance.
The genotypes and presence of virulence factors
unique to S. aureus were determined for all patients
Figure 1 Flow scheme for PCR/ESI-MS genotyping and characterization of S. aureus. DNA from nasal swabs was distributed into eight wells
of a microtiter plate, allowing 12 samples to be analyzed per plate. Each well contained two pairs of primers as indicated in Table 1. Following
PCR and desalting, amplicons were analyzed by ESI-MS. Amplicon masses were used to calculate base compositions—the A, G, C, and T counts
—of the PCR products. Comparison to a database of calculated base compositions of characterized strains allowed the determination of clonal
complexes and USA types and of the presence or absence of genes for virulence factors, toxins and antibiotic resistance determinants.
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colonized with S. aureus, regardless of whether the pa-
tient was co-colonized with CoNS. The genotype and
characterization results are shown in Table 3. The 59 S.
aureus isolates showed a remarkable diversity; the iso-
lates clustered into 21 genotypes as depicted by each
unique row in Table 3. One genotype was detected in 12
instances (Table 3) in this patient population, but 11 pa-
tients had unique genotypes. When examined from the
perspective of clonal complexes, the 21 unique molecular
genotypes belong to seven major clonal complexes (CC)
(Table 3). The most abundant genotypes were PCR/ESI-
MS type 1 (CC8) (19 patients), which correlates with
USA300, followed by PCR/ESI-MS type 2 (CC5), which
correlates with USA100 (12 patients). Eleven patients
had genotypes that were PCR/ESI-MS type 1 and were
positive for the PVL “R” variant; these genotypes are
consistent with the predominant community-associated
MRSA (CA-MRSA) in the US [20]. PCR/ESI-MS type 2
Table 2 Demographic characteristics of patients (n = 200) in the study
Variable All patients SA carriers MRSA carriers
(200 subjects) (59 subjects) (27 subjects)
Age
18-29 54 (27%) 16 (27%) 7 (26%)
30-39 43 (21.5%) 15 (25.5%) 4 (15%)
40-49 55 (27.5%) 13 (22%) 9 (33%)
50-59 39 (19.5%) 13 (22%) 7 (26%)
60 and up 9 (4.5%) 2 (3.5) 0 (0%)
Sex
Male 108 (54%) 26 (44%) 15 (55%)
Female 92 (46%) 33 (56%) 12 (45%)
Race
White/Hispanic 38 (19%) 14 (24%) 4 (15%)
Black 159 (79.5%) 45 (76%) 23 (85%)
Asian, Pacific Islander 2 (1%) 0 0
American Indian Alaskan Native 0 0 0
Other 1 (0.5%) 0 0
Hispanic/Spanish origin
Yes 3 (1.5%) 1 (2%) 0
No 195 (97.5%) 58 (98%) 27 (100%)
Unknown 2 (1%) 0 0
Primary complaint
Respiratory 26 (13%) 6 (10.5%) 3 (11%)
GI 22 (11%) 7 (12%) 3 (11%)
Dermatology 5 (2.5%) 2 (3%) 1 (4%)
Localized pain/weakness 87 (43.5%) 20 (35.5%) 11 (41%)
UGI 7 (3.5%) 3 (4.5%) 1 (4%)
Injury 14 (7%) 4 (6%) 2 (7.5%)
Cardiovascular 19 (9.5%) 8 (13.5%) 3 (11%)
Other 18 (9%) 9 (15%) 3 (11%)
General pain/weakness 2 (1%) 0 0
Antibiotic prescribed
Yes 39 (19%) 8 (14%) 5 (18.5%)
No 161 (79.5%) 49 (86%) 22 (71.5%)
Admission to hospital
Yes 29 (14.5%) 13 (22%) 7 (26%)
No 171 (75.5%) 46 (78%) 20 (74%)
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(CC5) was isolated from 12 patients; these isolates were
PVL negative and these organisms are consistent with
hospital-acquired MRSA (HA-MRSA). PCR/ESI-MS
types 1 and 2 (CC8 and CC5) represented slightly more
than half the organisms isolated from this patient popu-
lation; the remainders represented a plurality of CC ge-
notypes (CC45, CC30, CC15, CC45, CC59 or CC1) or
did not fit into a previously defined clonal complex
(Table 3).
Additional molecular resolution beyond the PCR/ESI-
MS type was provided by the presence or absence of the
lukD/E genes and the gene encoding the TSST-1 toxin.
Regions of two leukocidin toxin-producing operons were
amplified by a single pair of primers, BCT2095. A region
of the Panton-Valentine leukocidin (PVL) operon, which
includes the lukS-PV and lukF-PV genes, is targeted by a
primer pair that hybridizes across the junction of the 3′
end of lukS-PV and the 5′ end of lukF-PV [14]. The
same primer pair serendipitously detects and differenti-
ates by virtue of base composition a second leukotoxin-
encoding operon that contains the lukE and lukD genes.
Thus, analysis of an isolate had four potential outcomes:
PVL positive, lukE/D positive, both positive, or neither
positive. The lukD/E genes are generally correlated with
the clonal complex assignment. It was recently shown
that the gene encoding TSST-1 protein was associated
with PFGE type USA200 in 87% of isolates studied [23].
The tst gene was present in two of the four instances of
this genotype in our study. No mutations associated with
low-level mupirocin resistance were observed in the ileS
genes within this data set.
Risk factor analysis for colonization
Patient demographics, primary complaints, antibiotic
prescriptions and providers’ admission decisions were
evaluated for association with particular pathogens. No
independent factor was associated with any type of
colonization, however African Americans were more
likely to be colonized with USA 100/300 S. aureus geno-
types than other races (28 (62%) versus 3 (21%), p =
0.013).
Discussion
While some Emergency Departments have a high preva-
lence of MRSA isolated from patients with sporadic skin
and soft-tissue infections [24-26], limited research has ex-
plored nasal MRSA carriage in this population. The mecha-
nisms leading to S. aureus nasal carriage are multifactorial,
and an optimal fit between host and bacteria seems to be
essential [27]. This study demonstrated a significant preva-
lence of S. aureus, MRSA and drug-resistant CoNS nasal
colonization in a random sample of individuals seeking care
from the Emergency Department at The Johns Hopkins
Hospital. The prevalence of MRSA (13.5%) among nasal
isolates was somewhat greater than those estimated from
other studies that had a similar objective and sample popu-
lation [28]. Three studies performed outside healthcare fa-
cilities (i.e., isolated, semi-closed rural population [29],
urban poor in San Francisco [30], or university students in
Portugal [31]) that include a total of 4,452 people, showed a
pooled MRSA colonization prevalence of only 0.76% [32].
The prevalence of MRSA colonization in an inpatient set-
ting in a tertiary hospital was reported to be 0.18%–7.2%
[32,33]. Our findings were similar to the prevalence noted
in a study investigating the prevalence of MRSA among
newly arrested men in Baltimore (29.5% and 13.5% in our
study vs. 40.4% and 15.8% for S. aureus and MRSA preva-
lence, respectively) [34]. Other studies have identified three
risk factors for MRSA colonization: hospitalization within
the past 12 months [16], previous MRSA infection [17] and
injection drug use [18]. Because these risk factors had
already been identified, they were exclusion criteria in our
study. Although we evaluated patient demographics, pri-
mary complaints, chronic co-morbidities, antibiotic pre-
scriptions and providers’ admission decisions, none were
independent risk factors for MRSA colonization.
Figure 2 Distribution of S. aureus (orange), coagulase negative
staphylococci (stippled) and co-infections of both organisms
(orange stippled) within a collection of nasal swabs from 200
patients. Each category is subdivided according to the presence (+)
or absence (-) of the mecA and mupA genes, with the indication of
the corresponding number of isolates.
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Our data confirms recent epidemiologic data indi-
cating that nosocomial MRSA strains are present in
the community. Interestingly, there was substantial
genotypic diversity of S. aureus and MRSA types in
this the patient population. There was a significant
frequency of co-colonization of S. aureus and CoNS
(24 patients, 12%) and at least one third of patients
were colonized with a CoNS that had a high-level
mupirocin resistance gene (65 patients or 32%, non-
counting the S. aureus co-infections). This is con-
cerning because it has previously been reported that
the gene for high-level mupirocin resistance can be found
on conjugative plasmids that carry multiple resistance
determinants for other antimicrobial agents [21]. More-
over, this resistance has been shown to be transferable to
S. aureus [35], which has implications for mupirocin
decolonization strategies.
The PCR/ESI-MS methodology operates on an auto-
mated, high-throughput platform; patient specimens are
screened without culture and results are obtained in a
time frame similar to existing molecular tests. As data
from more extensive analysis of the S. aureus strains that
result in the hospital infections become available, add-
itional targets for genetic analysis of S. aureus can be
added. While a goal of this assay was to add targets that
provide information that have value for infection control
and tracking outbreaks in hospital settings, the limita-
tion to a current assay is the lack of resolution compared
to other technologies. We acknowledge that the inclu-
sion of typing for TSST or PVL, would probably not aid
in a clinical scenario, but might aid a research study
where predictors of subsequent infection in hospitalized
patients were being studied.
This study was performed in one location, the Johns
Hopkins Hospital Emergency Department and, therefore,
these results may not be applicable to other areas of the
United States. Although the ethnic diversity of the study
participants was similar to that of the population of
Johns Hopkins Hospital patients, of which 80% are
African American, these results may not be applicable to
more ethnically diverse areas of the United States. It also
should be noted that literature cites significant hetero-
geneity in the risk factors for nasal S. aureus and MRSA
colonization, as well as the fact that only surveying nasal
Table 3 Determination of PCR/ESI-MS type and clonal complexes of S. aureus from 59 infected patients1
Genotype Virulence/Toxin-encoding genes Number of instances
Clonal Complex PCR/ESI-MS or ST Type2 LukD/E PVL PVL Type TSST
CC8 1 - - - - 1
lukD/E+ - - - 6
lukD/E+ - - TSST+ 1
lukD/E+ PVL+ R - 11
7 lukD/E+ - - - 1
CC5 2 lukD/E+ - - - 12
CC30 3 - - - - 2
- - - TSST+ 2
CC15 12 lukD/E+ - - - 4
CC45 6 lukD/E+ PVL+ R - 1
- - - TSST+ 1
- - - - 3
CC59 5 - - - - 3
CC1 11 lukD/E+ - - - 1
ST:20 or ST:389 lukD/E+ - - - 3
ST:115, ST:116, or ST:118 - - - - 2
ST:115 - - - - 1
ST:25, ST:28, ST:564, ST:297 or ST369 lukD/E+ - - - 1
ST:109 or ST:540 - - - - 1
ST:630 or ST:683 - - - - 1
ST:188, ST:663 orST:758 - - - - 1
1PCR/ESI-MS type and clonal complex correlated as previously described [2].
2In cases where the PCR/ESI-MS was not conclusive the best match consistent with ST type is shown.
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swabs likely underestimates the prevalence of S. aureus
and MRSA carriage [4,36]. Several other, previously de-
scribed risk factors for S. aureus and MRSA colonization
(i.e. previous admission to hospital, or previous anti-
biotic use) were also investigated in this study. However,
there are other known factors for which we do not have
data, that might have significantly contributed to the
relatively high burden of MRSA encountered in our
study, including HIV status, diabetes, men who have sex
with men, recent incarceration, high-risk sexual behav-
ior, household members with SSTI, and hospital-
associated exposures [4]. It should be noted that this
was not a longitudinal study that would distinguish at
least three S aureus nasal carriage patterns in healthy in-
dividuals: persistent carriage, intermittent carriage, and
non-carriage. This distinction is important because per-
sistent carriers have higher S. aureus loads and a higher
risk of acquiring S. aureus infection [37,38]. A further
important limitation is that in the significant proportion
of patients (~40%) with both S. aureus and CNS, this
assay alone cannot distinguish for the presence of MRSA
or other resistance determinants being carried by S. aur-
eus. Thus, there remains the need for plating samples on
ChromAgar, which adds significantly to the turn-around
time for infection control purposes.
Conclusions
In conclusion, the prevalence of S. aureus and MRSA
colonization in a convenience sample of patients seeking
care in Emergency Department was 29.5% and 13.5%, re-
spectively. A substantial fraction of the S. aureus-colo-
nized patients were co-colonized with CoNS and high-
level mupirocin-resistant CoNS. These findings highlight
the importance of active surveillance studies to detect
MRSA colonization and/or infection among emergency
department patients. The molecular genotypes were dir-
ectly identified from nasal swabs by PCR/ESI-MS. The
ability to identify unique molecular signatures from
MRSA may allow infection control resources to be ef-
fectively focused and will enable tracking origins of out-
breaks in hospital settings. Determining the molecular
genotype of S. aureus during intake screening may prove
valuable if certain molecular genotypes become associ-
ated with increased infection risk.
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